Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 3/20 | 0.55 |
| ▸ | EBP | Q15125 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 4/20 | 0.40 |
| ▸ | CCR3 | P51677 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5226073 | 0.82 | CACNA1B (0.42) | CACNA1BBACE1 | |
| SCHEMBL5230728 | 0.80 | CACNA1B (0.47) | CACNA1BEBPSIGMAR1KCNA3CCR3 | |
| SCHEMBL5226924 | 0.79 | KCNA3 (0.65) | CACNA1BKCNA3CCR3L3MBTL1 | |
| SCHEMBL14431859 | 0.78 | CCR3 (0.54) | CACNA1BEBPSIGMAR1KCNA3CCR3 | |
| SCHEMBL5240018 | 0.76 | RAB9A (0.52) | CACNA1BEBPSIGMAR1KCNA3CCR3 | |
| SCHEMBL5239773 | 0.76 | CACNA1B (0.60) | CACNA1BMEN1 | |
| SCHEMBL14431920 | 0.75 | RAB9A (0.58) | CACNA1BEBPSIGMAR1KCNA3CCR3 | |
| SCHEMBL14431854 | 0.75 | SIGMAR1 (0.51) | CACNA1BEBPSIGMAR1KCNA3CCR3 | |
| SCHEMBL5237846 | 0.74 | SIGMAR1 (0.60) | CACNA1BEBPSIGMAR1KCNA3CCR3 | |
| SCHEMBL5235995 | 0.74 | CHRM4 (0.54) | CACNA1BEBPSIGMAR1KCNA3CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1818326-A1 | Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds | Eisai R&D Management Co., Ltd. (JP) | 2007-08-15 | — | — | EP | disclosed |
| EP-1818326-A1 | Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds | Eisai R&D Management Co., Ltd. (JP) | 2007-08-15 | — | — | EP | disclosed |
| EP-1254895-B1 | NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | EISAI R&D MAN CO LTD (JP) | 2007-05-23 | — | — | EP | disclosed |
| EP-1254895-B1 | NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | EISAI R&D MAN CO LTD (JP) | 2007-05-23 | — | — | EP | disclosed |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-04-20 | — | — | US | disclosed |
| US-6906072-B1 | Piperazine compound and pharmaceutical composition containing the compound | EISAI CO., LTD. (JP) | 2005-06-14 | — | — | US | disclosed |
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI CO., LTD. | 2004-11-04 | — | — | US | disclosed |
| EP-1254895-A1 | NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1D, CACNA1B, CACNA1E | CACNA1B 2/4885EBP 560/4885SIGMAR1 143/4885 |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1B, CACNA1E, CACNA1D | CACNA1B 1/4885EBP 964/4885SIGMAR1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.